7.68
-0.22(-2.78%)
Currency In USD
| Previous Close | 7.9 |
| Open | 7.87 |
| Day High | 8.07 |
| Day Low | 7.62 |
| 52-Week High | 33.68 |
| 52-Week Low | 5.14 |
| Volume | 1.11M |
| Average Volume | 1.17M |
| Market Cap | 415.02M |
| PE | -1.2 |
| EPS | -6.4 |
| Moving Average 50 Days | 24.54 |
| Moving Average 200 Days | 19.17 |
| Change | -0.22 |
If you invested $1000 in Upstream Bio, Inc. (UPB) since IPO date, it would be worth $349.09 as of March 01, 2026 at a share price of $7.68. Whereas If you bought $1000 worth of Upstream Bio, Inc. (UPB) shares 1 year ago, it would be worth $1,029.49 as of March 01, 2026 at a share price of $7.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
8 hours ago
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including r
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stag
Upstream Bio to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherlan